95TH GENERAL ASSEMBLY

State of Illinois

2007 and 2008

SB1355

Introduced 2/9/2007, by Sen. Carol Ronen

SYNOPSIS AS INTRODUCED:

225 ILCS 15/2	from Ch. 111, par. 5352
225 ILCS 15/4.1 new	
225 ILCS 15/4.2 new	
225 ILCS 15/4.3 new	
225 ILCS 15/4.4 new	
225 ILCS 15/4.5 new	
225 ILCS 15/4.6 new	
225 ILCS 15/15	from Ch. 111, par. 5365
225 ILCS 65/5-10	
225 ILCS 85/3	from Ch. 111, par. 4123
225 ILCS 85/4	from Ch. 111, par. 4124
720 ILCS 570/102	from Ch. 56 1/2, par. 1102

Amends the Clinical Psychologist Licensing Act. Provides that the Clinical Psychologists Licensing and Disciplinary Board shall grant certification as medical psychologists to doctoral level psychologists licensed under the Act, and that this certification shall grant medical psychologists prescriptive authority to prescribe and dispense those drugs used in the treatment of mental, emotional, and psychological disorders. Sets forth provisions concerning application requirements, renewal, prescribing practices, controlled substance prescriptive authority, and State Board of Pharmacy interaction. Amends the Nursing and Advanced Practice Nursing Act, the Pharmacy Practice Act of 1987, and the Illinois Controlled Substances Act to make related changes.

LRB095 04986 RAS 25052 b

FISCAL NOTE ACT MAY APPLY

A BILL FOR

1

AN ACT concerning regulation.

2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly:

4 Section 5. The Clinical Psychologist Licensing Act is 5 amended by changing Sections 2 and 15 and by adding Sections 4.1, 4.2, 4.3, 4.4, 4.5, and 4.6 as follows: 6 7 (225 ILCS 15/2) (from Ch. 111, par. 5352) 8 (Section scheduled to be repealed on January 1, 2017) 9 Sec. 2. Definitions. As used in this Act: (1) "Department" means the Department of Financial and 10 11 Professional Regulation. (2) "Secretary" means the Secretary of Financial and 12 13 Professional Regulation. 14 (3) "Board" means the Clinical Psychologists Licensing and Disciplinary Board appointed by the Secretary. 15 16 (4) "Person" means an individual, association, 17 partnership or corporation. "Clinical psychology" means 18 (5)the independent 19 evaluation, classification and treatment of mental. 20 emotional, behavioral or nervous disorders or conditions, 21 developmental disabilities, alcoholism and substance 22 abuse, disorders of habit or conduct, the psychological aspects of physical illness. The practice of clinical 23

psychology includes psychoeducational evaluation, therapy, 1 2 remediation and consultation, the use of psychological and 3 neuropsychological testing, assessment, psychotherapy, psychoanalysis, hypnosis, biofeedback, and behavioral 4 5 modification when any of these are used for the purpose of preventing or eliminating psychopathology, or for the 6 7 amelioration of psychological disorders of individuals or groups. "Clinical psychology" does not include the use of 8 9 hypnosis by unlicensed persons pursuant to Section 3.

10 (6) A person represents himself to be a "clinical 11 psychologist" within the meaning of this Act when he or she 12 holds himself out to the public by any title or description 13 services incorporating the words "psychological", of "psychologic", "psychologist", "psychology", or "clinical 14 15 psychologist" or under such title or description offers to 16 render or renders clinical psychological services as 17 defined in paragraph (7) of this Section to individuals, corporations, or the public for remuneration. 18

(7) "Clinical psychological services" refers to any
services under paragraph (5) of this Section if the words
"psychological", "psychologic", "psychologist",
"psychology" or "clinical psychologist" are used to
describe such services by the person or organization
offering to render or rendering them.

25 (8) "Drugs" has the meaning given to that term in the
 26 Pharmacy Practice Act of 1987.

- 3 - LRB095 04986 RAS 25052 b

1	(9) "Medicines" has the meaning given to that term in
2	the Pharmacy Practice Act of 1987.
3	(10) "Prescription" means an order for a drug,
4	laboratory test, or any medicines, devices, or treatments,
5	including controlled substances, as defined by State law.
6	(11) "Prescriptive authority" means the authority to
7	prescribe and dispense drugs, medicines, or other
8	treatment procedures.
9	(12) "Medical psychologist" means a licensed, doctoral
10	level psychologist who has undergone specialized training,
11	has passed an examination accepted by the Board, and has
12	received a current certificate granting prescriptive
13	authority that has not been revoked or suspended from the
14	Board.
15	This Act shall not apply to persons lawfully carrying on
16	their particular profession or business under any valid
17	existing regulatory Act of the State.
18	(Source: P.A. 94-870, eff. 6-16-06.)
19	(225 ILCS 15/4.1 new)
20	Sec. 4.1. Medical psychologist certification; prescriptive
21	authority. The Board shall grant certification as medical
22	psychologists to doctoral level psychologists licensed under
23	this Act. This certification shall grant medical psychologists

24 prescriptive authority to prescribe and dispense those drugs

25 <u>used in the treatment of mental, emotional, and psychological</u>

95 04986 RAS 25052 b
5

1	disorders in accordance with applicable State and federal laws.
2	The Board shall develop and implement procedures and
3	criteria for reviewing educational and training credentials
4	for the certification process and the extent of prescriptive
5	authority, in accordance with current standards of
6	professional practice. The Board may seek the advice of other
7	State agencies with relevant experience in devising
8	certification procedures and criteria.

9	(225 ILCS 15/4.2 new)
10	Sec. 4.2. Medical psychologist certification application
11	requirements.
12	(a) The Department shall grant medical psychologist
13	certification to a psychologist who applies for certification
14	and demonstrates, by official transcript or other official
15	evidence satisfactory to the Board, all of the following:
16	(1) The completion of a doctoral program in psychology
17	from a regionally-accredited university or professional
18	school or, if the program is not accredited at the time of
19	graduation, completion of a doctoral program in psychology
20	that meets recognized acceptable professional standards,
21	as determined by the Board.
22	(2) Possession of a current and valid license to
23	practice psychology in this State.
24	(3) The completion of an organized program of intensive
25	didactic instruction, as defined by the Board, within the

- 5 - LRB095 04986 RAS 25052 b

1	5-year period immediately before the date of application,
2	consisting of a minimum of 300 contact hours and the
3	following core areas of instruction:
4	(A) neuroscience;
5	(B) pharmacology;
6	(C) psychopharmacology;
7	(D) physiology;
8	(E) pathophysiology;
9	(F) appropriate and relevant physical and
10	laboratory assessment; and
11	(G) clinical pharmacotherapeutics.
12	(4) The procurement of supervised and relevant
13	clinical experience sufficient to achieve competency in
14	the treatment of a diverse patient population under the
15	direction of qualified practitioners, as determined by the
16	Board, within the 5-year period immediately preceding the
17	date of application that includes the pharmacological
18	treatment of a minimum of 100 patients under the full
19	supervision and control of a designated qualified
20	practitioner who shall then certify the clinical
21	competency of the candidate for certification; and the
22	completion of a minimum of 80 hours of supervised training
23	in physical assessment under the full supervision and
24	control of a designated qualified practitioner.
25	(5) The successful completion of a certifying
26	examination stipulated by the Board.

- 6 - LRB095 04986 RAS 25052 b

1	(b) The Department shall grant certification to a
2	psychologist who applies for certification as a medical
3	psychologist and has completed the requirements specified in
4	subsection (a), except that the applicant has met the academic
5	requirements in paragraph (3) of subsection (a) more than 5
6	years prior to the application for prescriptive authority, if
7	the applicant has completed 24 hours of continuing education in
8	the 2 years immediately prior to application, as specified in
9	Section 4.3 of this Act.
10	(225 ILCS 15/4.3 new)
11	Sec. 4.3. Renewal of medical psychologist certification.
12	(a) The Board shall establish by rule a method for the
13	annual renewal of medical psychologist certification at the
14	time of or in conjunction with the renewal of clinical
15	psychology licenses.
16	(b) Each applicant for renewal of medical psychologist
17	certification shall present satisfactory evidence to the Board
18	demonstrating the completion of 24 required hours of
19	instruction relevant to prescriptive authority during the 24
20	months prior to application for renewal.
21	(225 ILCS 15/4.4 new)
22	Sec. 4.4. Prescribing practices.

(a) Every prescription by a medical psychologist shall (i)
 comply with all applicable State and federal laws, (ii) be

	SB1355 - 7 - LRB095 04986 RAS 25052 b
1	identified as issued by the psychologist as a "medical
2	psychologist", and (iii) include the medical psychologist's
3	identification number, as assigned by the Board.
4	(b) Records of all prescriptions shall be maintained in
5	patient records.
6	(c) A medical psychologist shall not delegate the
7	prescriptive authority to any other person.
8	(d) A medical psychologist shall maintain an ongoing
9	collaborative relationship with the health care practitioner
10	who oversees the patient's general medical care to ensure that
11	(i) necessary medical examinations are conducted, (ii) the
12	psychotropic medication is appropriate for the patient's
13	medical condition, (iii) and significant changes in the
14	patient's medical or psychological condition are discussed.
15	(e) In this Section:
16	"Collaborative relationship" means a cooperative
17	working relationship between a medical psychologist and a
18	health care practitioner in the provision of patient care,
19	including diagnosis and cooperation in the management and
20	delivery of physical and mental health care.
21	"Health care practitioner" means a physician,
22	osteopathic physician, or nurse practitioner.
23	(225 ILCS 15/4.5 new)
24	Sec. 4.5. Controlled substance prescriptive authority.
25	(a) When authorized to prescribe controlled substances, a

	SB1355 - 8 - LRB095 04986 RAS 25052 b
1	medical psychologist shall file, in a timely manner, any
2	individual Drug Enforcement Agency (DEA) registrations and
3	identification numbers with the Board.
4	(b) The Board shall maintain current records of every
5	medical psychologist, including DEA registration and
6	identification numbers.
7	(225 ILCS 15/4.6 new)
8	Sec. 4.6. State Board of Pharmacy interaction.
9	(a) The Board shall transmit to the State Board of Pharmacy
10	an annual list of medical psychologists containing the
11	following information:
12	(1) the name of the psychologist;
13	(2) the medical psychologist's identification number
14	assigned by the Board; and
15	(3) the effective dates of the medical psychologist's
16	certification.
17	(b) The Board shall promptly forward to the Board of
18	Pharmacy the names and titles of psychologists added to or
19	deleted from the annual list of medical psychologists.
20	(c) The Board shall notify the State Board of Pharmacy, in
21	a timely manner, upon termination, suspension, or
22	reinstatement of a psychologist's certification as a medical
23	psychologist.

24

(225 ILCS 15/15) (from Ch. 111, par. 5365)

1

(Section scheduled to be repealed on January 1, 2017)

2 Sec. 15. Disciplinary action; grounds. The Department may 3 refuse to issue, refuse to renew, suspend, or revoke any license, or may place on probation, censure, reprimand, or take 4 5 other disciplinary action deemed appropriate bv the Department, including the imposition of fines not to exceed 6 7 \$10,000 for each violation, with regard to any license issued under the provisions of this Act for any one or a combination 8 9 of the following reasons:

10 (1) Conviction of, or entry of a plea of guilty or nolo 11 contendere to, any crime that is a felony under the laws of 12 the United States or any state or territory thereof or that 13 is a misdemeanor of which an essential element is 14 dishonesty, or any crime that is directly related to the 15 practice of the profession.

16 (2) Gross negligence in the rendering of clinical17 psychological services.

18 (3) Using fraud or making any misrepresentation in
19 applying for a license or in passing the examination
20 provided for in this Act.

(4) Aiding or abetting or conspiring to aid or abet a
person, not a clinical psychologist licensed under this
Act, in representing himself or herself as so licensed or
in applying for a license under this Act.

(5) Violation of any provision of this Act or the rulespromulgated thereunder.

1

2

3

4

5

6

7

8

9

(6) Professional connection or association with any person, firm, association, partnership or corporation holding himself, herself, themselves, or itself out in any manner contrary to this Act.

(7) Unethical, unauthorized or unprofessional conduct as defined by rule. In establishing those rules, the Department shall consider, though is not bound by, the ethical standards for psychologists promulgated by recognized national psychology associations.

10 (8) Aiding or assisting another person in violating any
 11 provisions of this Act or the rules promulgated thereunder.

(9) Failing to provide, within 60 days, information in
 response to a written request made by the Department.

(10) Habitual or excessive use or addiction to alcohol,
narcotics, stimulants, or any other chemical agent or drug
that results in a clinical psychologist's inability to
practice with reasonable judgment, skill or safety.

18 (11) Discipline by another state, territory, the 19 District of Columbia or foreign country, if at least one of 20 the grounds for the discipline is the same or substantially 21 equivalent to those set forth herein.

(12) Directly or indirectly giving or receiving from
any person, firm, corporation, association or partnership
any fee, commission, rebate or other form of compensation
for any professional service not actually or personally
rendered.

(13) A finding by the Board that the licensee, after
 having his or her license placed on probationary status has
 violated the terms of probation.

4 (14) Willfully making or filing false records or
5 reports, including but not limited to, false records or
6 reports filed with State agencies or departments.

7 (15) Physical illness, including but not limited to,
8 deterioration through the aging process, mental illness or
9 disability that results in the inability to practice the
10 profession with reasonable judgment, skill and safety.

(16) Willfully failing to report an instance of
 suspected child abuse or neglect as required by the Abused
 and Neglected Child Reporting Act.

14 (17) Being named as a perpetrator in an indicated 15 report by the Department of Children and Family Services 16 pursuant to the Abused and Neglected Child Reporting Act, 17 and upon proof by clear and convincing evidence that the 18 licensee has caused a child to be an abused child or 19 neglected child as defined in the Abused and Neglected 20 Child Reporting Act.

(18) Violation of the Health Care Worker Self-Referral
 Act.

(19) Making a material misstatement in furnishing
information to the Department, any other State or federal
agency, or any other entity.

26

(20) Failing to report to the Department any adverse

judgment, settlement, or award arising from a liability claim related to an act or conduct similar to an act or conduct that would constitute grounds for action as set forth in this Section.

5 (21) Failing to report to the Department any adverse final action taken against a licensee or applicant by 6 another licensing jurisdiction, including any other state 7 8 or territory of the United States or any foreign state or 9 country, or any peer review body, health care institution, professional society or association related 10 to the 11 profession, governmental agency, law enforcement agency, 12 or court for an act or conduct similar to an act or conduct 13 that would constitute grounds for disciplinary action as set forth in this Section. 14

The entry of an order by any circuit court establishing 15 16 that any person holding a license under this Act is subject to 17 involuntary admission or judicial admission as provided for in Health and Developmental Disabilities Code, 18 the Mental 19 operates as an automatic suspension of that license. That 20 person may have his or her license restored only upon the determination by a circuit court that the patient is no longer 21 22 subject to involuntary admission or judicial admission and the 23 issuance of an order so finding and discharging the patient and 24 upon the Board's recommendation to the Department that the 25 license be restored. Where the circumstances so indicate, the 26 Board may recommend to the Department that it require an

1 examination prior to restoring any license so automatically 2 suspended.

The Department may refuse to issue or may suspend the license of any person who fails to file a return, or to pay the tax, penalty or interest shown in a filed return, or to pay any final assessment of the tax penalty or interest, as required by any tax Act administered by the Illinois Department of Revenue, until such time as the requirements of any such tax Act are satisfied.

In enforcing this Section, the Board upon a showing of a 10 11 possible violation may compel any person licensed to practice 12 under this Act, or who has applied for licensure or 13 certification pursuant to this Act, to submit to a mental or 14 physical examination, or both, as required by and at the 15 expense of the Department. The examining physicians or clinical 16 psychologists shall be those specifically designated by the 17 Board. The Board or the Department may order the examining physician or clinical psychologist to present testimony 18 concerning this mental or physical examination of the licensee 19 20 or applicant. No information shall be excluded by reason of any common law or statutory privilege relating to communications 21 22 between the licensee or applicant and the examining physician 23 or clinical psychologist. The person to be examined may have, 24 at his or her own expense, another physician or clinical 25 psychologist of his or her choice present during all aspects of 26 the examination. Failure of any person to submit to a mental or

1 physical examination, when directed, shall be grounds for 2 suspension of a license until the person submits to the 3 examination if the Board finds, after notice and hearing, that 4 the refusal to submit to the examination was without reasonable 5 cause.

If the Board finds a person unable to practice because of 6 the reasons set forth in this Section, the Board may require 7 that person to submit to care, counseling or treatment by 8 9 physicians or clinical psychologists approved or designated by 10 the Board, as a condition, term, or restriction for continued, 11 reinstated, or renewed licensure to practice; or, in lieu of 12 care, counseling or treatment, the Board may recommend to the Department to file a complaint to immediately suspend, revoke 13 or otherwise discipline the license of the person. Any person 14 whose license was granted, continued, reinstated, renewed, 15 16 disciplined or supervised subject to such terms, conditions or 17 restrictions, and who fails to comply with such terms, conditions or restrictions, shall be referred to the Secretary 18 for a determination as to whether the person shall have his or 19 her license suspended immediately, pending a hearing by the 20 Board. 21

In instances in which the Secretary immediately suspends a person's license under this Section, a hearing on that person's license must be convened by the Board within 15 days after the suspension and completed without appreciable delay. The Board shall have the authority to review the subject person's record of treatment and counseling regarding the impairment, to the extent permitted by applicable federal statutes and regulations safeguarding the confidentiality of medical records.

5 A person licensed under this Act and affected under this 6 Section shall be afforded an opportunity to demonstrate to the 7 Board that he or she can resume practice in compliance with 8 acceptable and prevailing standards under the provisions of his 9 or her license.

10 <u>The Board shall prescribe, by rule, criteria for</u> 11 <u>disciplining, suspending, or revoking the prescriptive</u> 12 <u>authority of a medical psychologist. The Board shall have the</u> 13 <u>power and duty to require remediation, suspension, or</u> 14 <u>revocation of a medical psychologist's certification for a</u> 15 <u>specified period of time determined by the Board.</u>

16 (Source: P.A. 94-870, eff. 6-16-06.)

Section 10. The Nursing and Advanced Practice Nursing Actis amended by changing Section 5-10 as follows:

19

(225 ILCS 65/5-10)

20 (Section scheduled to be repealed on January 1, 2008)
21 Sec. 5-10. Definitions. Each of the following terms, when
22 used in this Act, shall have the meaning ascribed to it in this
23 Section, except where the context clearly indicates otherwise:
24 (a) "Department" means the Department of Professional

1 Regulation.

2 (b) "Director" means the Director of Professional3 Regulation.

4 (c) "Board" means the Board of Nursing appointed by the 5 Director.

6 (d) "Academic year" means the customary annual schedule of 7 courses at a college, university, or approved school, 8 customarily regarded as the school year as distinguished from 9 the calendar year.

10 (e) "Approved program of professional nursing education" 11 and "approved program of practical nursing education" are 12 programs of professional or practical nursing, respectively, 13 approved by the Department under the provisions of this Act.

14 (f) "Nursing Act Coordinator" means a registered 15 professional nurse appointed by the Director to carry out the 16 administrative policies of the Department.

(g) "Assistant Nursing Act Coordinator" means a registered professional nurse appointed by the Director to assist in carrying out the administrative policies of the Department.

20

(h) "Registered" is the equivalent of "licensed".

(i) "Practical nurse" or "licensed practical nurse" means a person who is licensed as a practical nurse under this Act and practices practical nursing as defined in paragraph (j) of this Section. Only a practical nurse licensed under this Act is entitled to use the title "licensed practical nurse" and the abbreviation "L.P.N.".

(j) "Practical nursing" means the performance of nursing 1 2 acts requiring the basic nursing knowledge, judgement, and skill acquired by means of completion of an approved practical 3 education program. Practical nursing includes 4 nursing 5 assisting in the nursing process as delegated by and under the 6 direction of a registered professional nurse. The practical 7 nurse may work under the direction of a licensed physician, 8 dentist, podiatrist, or other health care professional 9 determined by the Department.

10 (k) "Registered Nurse" or "Registered Professional Nurse" 11 means a person who is licensed as a professional nurse under 12 this Act and practices nursing as defined in paragraph (l) of 13 this Section. Only a registered nurse licensed under this Act 14 is entitled to use the titles "registered nurse" and 15 "registered professional nurse" and the abbreviation, "R.N.".

16 (1)"Registered professional nursing practice" includes 17 all nursing specialities and means the performance of any nursing act based upon professional knowledge, judgment, and 18 19 skills acquired by means of completion of an approved 20 program. registered professional nursing education Α 21 registered professional nurse provides nursing care 22 emphasizing the importance of the whole and the interdependence 23 of its parts through the nursing process to individuals, groups, families, or communities, that includes but is not 24 25 limited to: (1) the assessment of healthcare needs, nursing 26 diagnosis, planning, implementation, and nursing evaluation;

(2) the promotion, maintenance, and restoration of health; (3) 1 2 counseling, patient education, health education, and patient advocacy; (4) the administration of medications and treatments 3 as prescribed by a physician licensed to practice medicine in 4 5 all of its branches, a licensed dentist, a licensed podiatrist, a medical psychologist, or a licensed optometrist or as 6 7 prescribed by a physician assistant in accordance with written quidelines required under the Physician Assistant Practice Act 8 9 of 1987 or by an advanced practice nurse in accordance with a 10 written collaborative agreement required under the Nursing and 11 Advanced Practice Nursing Act; (5) the coordination and 12 management of the nursing plan of care; (6) the delegation to 13 and supervision of individuals who assist the registered professional nurse implementing the plan of care; and (7) 14 teaching and supervision of nursing students. The foregoing 15 16 shall not be deemed to include those acts of medical diagnosis 17 or prescription of therapeutic or corrective measures that are properly performed only by physicians licensed in the State of 18 Illinois. 19

20 "Current nursing practice update course" (m) means a 21 planned nursing education curriculum approved by the 22 Department consisting of activities that have educational 23 objectives, instructional methods, content or subject matter, clinical practice, and evaluation methods, related to basic 24 25 review and updating content and specifically planned for those nurses previously licensed in the United States or its 26

1 territories and preparing for reentry into nursing practice.

2 (n) "Professional assistance program for nurses" means a 3 professional assistance program that meets criteria established by the Board of Nursing and approved by the 4 5 Director, which provides a non-disciplinary treatment approach 6 for nurses licensed under this Act whose ability to practice is 7 compromised by alcohol or chemical substance addiction. (Source: P.A. 90-61, eff. 12-30-97; 90-248, eff. 1-1-98; 8

9 90-655, eff. 7-30-98; 90-742, eff. 8-13-98.)

Section 15. The Pharmacy Practice Act of 1987 is amended by changing Sections 3 and 4 as follows:

12 (225 ILCS 85/3) (from Ch. 111, par. 4123)

13 (Section scheduled to be repealed on January 1, 2008)

Sec. 3. Definitions. For the purpose of this Act, except where otherwise limited therein:

(a) "Pharmacy" or "drugstore" means and includes every 16 17 shop, pharmacy department, or other place store, where pharmaceutical care is provided by a pharmacist (1) where 18 drugs, medicines, or poisons are dispensed, sold or offered for 19 20 sale at retail, or displayed for sale at retail; or (2) where 21 prescriptions physicians, dentists, veterinarians, of 22 podiatrists, medical psychologists, or therapeutically certified optometrists, within the limits of their licenses, 23 are compounded, filled, or dispensed; or (3) which has upon it 24

or displayed within it, or affixed to or used in connection 1 2 with it, a sign bearing the word or words "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical Care", "Apothecary", 3 4 "Drugstore", "Medicine Store", "Prescriptions", "Drugs", 5 "Medicines", or any word or words of similar or like import, 6 either in the English language or any other language; or (4) 7 where the characteristic prescription sign (Rx) or similar 8 design is exhibited; or (5) any store, or shop, or other place 9 with respect to which any of the above words, objects, signs or 10 designs are used in any advertisement.

(b) "Drugs" means and includes (1) articles recognized in 11 12 the official United States Pharmacopoeia/National Formulary 13 (USP/NF), or any supplement thereto and being intended for and 14 having for their main use the diagnosis, cure, mitigation, 15 treatment or prevention of disease in man or other animals, as 16 approved by the United States Food and Drug Administration, but 17 does not include devices or their components, parts, or accessories; and (2) all other articles intended for and having 18 19 for their main use the diagnosis, cure, mitigation, treatment 20 or prevention of disease in man or other animals, as approved by the United States Food and Drug Administration, but does not 21 22 include devices or their components, parts, or accessories; and 23 (3) articles (other than food) having for their main use and intended to affect the structure or any function of the body of 24 25 man or other animals; and (4) articles having for their main 26 use and intended for use as a component or any articles

specified in clause (1), (2) or (3); but does not include devices or their components, parts or accessories.

3 (c) "Medicines" means and includes all drugs intended for
4 human or veterinary use approved by the United States Food and
5 Drug Administration.

6 "Practice of pharmacy" means the provision (d) of 7 pharmaceutical care to patients as determined by the 8 pharmacist's professional judgment in the following areas, 9 which may include but are not limited to (1) patient 10 counseling, (2) interpretation and assisting in the monitoring 11 of appropriate drug use and prospective drug utilization 12 review, (3) providing information on the therapeutic values, 13 reactions, drug interactions, side effects, uses, selection of medications and medical devices, and outcome of drug therapy, 14 15 (4) participation in drug selection, drug monitoring, drug 16 utilization review, evaluation, administration, 17 interpretation, application of pharmacokinetic and laboratory data to design safe and effective drug regimens, (5) drug 18 research (clinical and scientific), and (6) compounding and 19 20 dispensing of drugs and medical devices.

(e) "Prescription" means and includes any written, oral, facsimile, or electronically transmitted order for drugs or medical devices, issued by a physician licensed to practice medicine in all its branches, dentist, veterinarian, or podiatrist, or therapeutically certified optometrist, within the limits of their licenses, by a physician assistant in

accordance with subsection (f) of Section 4, or by an advanced 1 2 practice nurse in accordance with subsection (g) of Section 4, 3 containing the following: (1) name of the patient; (2) date when prescription was issued; (3) name and strength of drug or 4 5 description of the medical device prescribed; and (4) quantity, 6 (5) directions for use, (6) prescriber's name, address and 7 signature, and (7) DEA number where required, for controlled 8 substances. DEA numbers shall not be required on inpatient drug 9 orders.

10 (f) "Person" means and includes a natural person, 11 copartnership, association, corporation, government entity, or 12 any other legal entity.

13 (g) "Department" means the Department of Professional 14 Regulation.

(h) "Board of Pharmacy" or "Board" means the State Board ofPharmacy of the Department of Professional Regulation.

17 (i) "Director" means the Director of Professional18 Regulation.

(j) "Drug product selection" means the interchange for a prescribed pharmaceutical product in accordance with Section 25 of this Act and Section 3.14 of the Illinois Food, Drug and Cosmetic Act.

(k) "Inpatient drug order" means an order issued by an authorized prescriber for a resident or patient of a facility licensed under the Nursing Home Care Act or the Hospital Licensing Act, or "An Act in relation to the founding and

operation of the University of Illinois Hospital and the 1 2 conduct of University of Illinois health care programs", approved July 3, 1931, as amended, or a facility which is 3 operated by the Department of Human Services (as successor to 4 5 the Department of Mental Health and Developmental 6 Disabilities) or the Department of Corrections.

7 (k-5) "Pharmacist" means an individual health care
8 professional and provider currently licensed by this State to
9 engage in the practice of pharmacy.

10 (1) "Pharmacist in charge" means the licensed pharmacist 11 whose name appears on a pharmacy license and who is responsible 12 for all aspects of the operation related to the practice of 13 pharmacy.

(m) "Dispense" means the delivery of drugs and medical 14 15 devices, in accordance with applicable State and federal laws 16 and regulations, to the patient or the patient's representative 17 authorized to receive these products, including the preparation, compounding, packaging, and labeling necessary 18 for delivery, computer entry, and verification of medication 19 20 orders and prescriptions, and any recommending or advising concerning the contents and therapeutic values and uses 21 22 thereof. "Dispense" does not mean the physical delivery to a 23 patient or a patient's representative in a home or institution by a designee of a pharmacist or by common carrier. "Dispense" 24 25 also does not mean the physical delivery of a drug or medical device to a patient or patient's representative by a 26

1 pharmacist's designee within a pharmacy or drugstore while the 2 pharmacist is on duty and the pharmacy is open.

3 (n) "Mail-order pharmacy" means a pharmacy that is located 4 in a state of the United States, other than Illinois, that 5 delivers, dispenses or distributes, through the United States 6 Postal Service or other common carrier, to Illinois residents, 7 any substance which requires a prescription.

preparation, 8 "Compounding" means the (0) mixing, 9 assembling, packaging, or labeling of a drug or medical device: 10 (1) as the result of a practitioner's prescription drug order 11 or initiative that is dispensed pursuant to a prescription in 12 the course of professional practice; or (2) for the purpose of, or incident to, research, teaching, or chemical analysis; or 13 14 (3) in anticipation of prescription drug orders based on 15 routine, regularly observed prescribing patterns.

(p) "Confidential information" means information, maintained by the pharmacist in the patient's records, released only (i) to the patient or, as the patient directs, to other practitioners and other pharmacists or (ii) to any other person authorized by law to receive the information.

"Prospective drug review" or "drug utilization 21 (q) 22 evaluation" means a screening for potential drug therapy 23 to therapeutic duplication, problems due drug-disease contraindications, drug-drug interactions (including serious 24 25 interactions with nonprescription or over-the-counter drugs), drug-food interactions, incorrect drug dosage or duration of 26

1 drug treatment, drug-allergy interactions, and clinical abuse 2 or misuse.

(r) "Patient counseling" means the communication between a 3 pharmacist or a student pharmacist under the direct supervision 4 5 of a pharmacist and a patient or the patient's representative about the patient's medication or device for the purpose of 6 optimizing proper use of prescription medications or devices. 7 8 The offer to counsel by the pharmacist or the pharmacist's 9 designee, and subsequent patient counseling by the pharmacist 10 or student pharmacist, shall be made in a face-to-face 11 communication with the patient or patient's representative 12 unless, in the professional judgment of the pharmacist, a 13 face-to-face communication deemed is inappropriate or unnecessary. In that instance, the offer to counsel or patient 14 15 counseling may be made in a written communication, bv 16 telephone, or in a manner determined by the pharmacist to be 17 appropriate.

(s) "Patient profiles" or "patient drug therapy record" means the obtaining, recording, and maintenance of patient prescription information, including prescriptions for controlled substances, and personal information.

(t) "Pharmaceutical care" includes, but is not limited to, the act of monitoring drug use and other patient care services intended to achieve outcomes that improve the patient's quality of life but shall not include the sale of over-the-counter drugs by a seller of goods and services who does not dispense 1 prescription drugs.

2 "Medical device" means an instrument, apparatus, (u) 3 implement, machine, contrivance, implant, in vitro reagent, or 4 other similar or related article, including any component part 5 or accessory, required under federal law to bear the label 6 "Caution: Federal law requires dispensing by or on the order of 7 a physician". A seller of goods and services who, only for the purpose of retail sales, compounds, sells, rents, or leases 8 9 medical devices shall not, by reasons thereof, be required to 10 be a licensed pharmacy.

(v) "Unique identifier" means an electronic signature, handwritten signature or initials, thumb print, or other acceptable individual biometric or electronic identification process as approved by the Department.

(w) "Current usual and customary retail price" means the actual price that a pharmacy charges a retail purchaser. (Source: P.A. 93-571, eff. 8-20-03; 93-1075, eff. 1-18-05; 94-459, eff. 1-1-06.)

19 (225 ILCS 85/4) (from Ch. 111, par. 4124)

20 (Section scheduled to be repealed on January 1, 2008)

21 Sec. 4. Exemptions. Nothing contained in any Section of 22 this Act shall apply to, or in any manner interfere with:

(a) the lawful practice of any physician licensed to
 practice medicine in all of its branches, dentist, podiatrist,
 veterinarian, <u>medical psychologist</u>, or therapeutically or

diagnostically certified optometrist within the limits of his or her license, or prevent him or her from supplying to his or her bona fide patients such drugs, medicines, or poisons as may seem to him appropriate;

5

SB1355

(b) the sale of compressed gases;

6 (C) the sale of patent or proprietary medicines and 7 household remedies when sold in original and unbroken packages 8 only, if such patent or proprietary medicines and household 9 remedies be properly and adequately labeled as to content and 10 usage and generally considered and accepted as harmless and 11 nonpoisonous when used according to the directions on the 12 label, and also do not contain opium or coca leaves, or any 13 compound, salt or derivative thereof, or any drug which, 14 according to the latest editions of the following authoritative 15 pharmaceutical treatises and standards, namely, The United 16 States Pharmacopoeia/National Formulary (USP/NF), the United 17 States Dispensatory, and the Accepted Dental Remedies of the Dental Therapeutics of the 18 Council of American Dental 19 Association or any or either of them, in use on the effective 20 date of this Act, or according to the existing provisions of 21 the Federal Food, Drug, and Cosmetic Act and Regulations of the 22 Department of Health and Human Services, Food and Drug 23 Administration, promulgated thereunder now in effect, is designated, described or considered as a narcotic, hypnotic, 24 25 habit forming, dangerous, or poisonous drug;

26

(d) the sale of poultry and livestock remedies in original

1 and unbroken packages only, labeled for poultry and livestock
2 medication;

3 (e) the sale of poisonous substances or mixture of poisonous substances, in unbroken packages, for nonmedicinal 4 5 use in the arts or industries or for insecticide purposes; provided, they are properly and adequately labeled as to 6 content and such nonmedicinal usage, in conformity with the 7 provisions of all applicable federal, state and local laws and 8 9 regulations promulgated thereunder now in effect relating 10 thereto and governing the same, and those which are required 11 under such applicable laws and regulations to be labeled with 12 the word "Poison", are also labeled with the word "Poison" 13 printed thereon in prominent type and the name of a readily obtainable antidote with directions for its administration; 14

(f) the delegation of limited prescriptive authority by a 15 16 physician licensed to practice medicine in all its branches to 17 a physician assistant under Section 7.5 of the Physician Assistant Practice Act of 1987. This delegated authority may 18 but is not required to include prescription of Schedule III, 19 20 IV, or V controlled substances, as defined in Article II of the 21 Illinois Controlled Substances Act, in accordance with written 22 quidelines under Section 7.5 of the Physician Assistant 23 Practice Act of 1987; and

(g) The delegation of limited prescriptive authority by a
 physician licensed to practice medicine in all its branches to
 an advanced practice nurse in accordance with a written

collaborative agreement under Sections 15-15 and 15-20 of the
Nursing and Advanced Practice Nursing Act. This delegated
authority may but is not required to include the prescription
of Schedule III, IV, or V controlled substances as defined in
Article II of the Illinois Controlled Substances Act.
(Source: P.A. 90-116, eff. 7-14-97; 90-253, eff. 7-29-97;

7 90-655, eff. 7-30-98; 90-742, eff. 8-13-98.)

8 Section 20. The Illinois Controlled Substances Act is 9 amended by changing Section 102 as follows:

10 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

11 Sec. 102. Definitions. As used in this Act, unless the 12 context otherwise requires:

(a) "Addict" means any person who habitually uses any drug, chemical, substance or dangerous drug other than alcohol so as to endanger the public morals, health, safety or welfare or who is so far addicted to the use of a dangerous drug or controlled substance other than alcohol as to have lost the power of self control with reference to his addiction.

(b) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient, research subject, or animal (as defined by the Humane Euthanasia in Animal Shelters Act) by:

24

(1) a practitioner (or, in his presence, by his

1 authorized agent),

2 (2) the patient or research subject at the lawful 3 direction of the practitioner, or

4

(3) a euthanasia technician as defined by the Humane 5 Euthanasia in Animal Shelters Act.

(c) "Agent" means an authorized person who acts on behalf 6 of or at the direction of a manufacturer, distributor, or 7 dispenser. It does not include a common or contract carrier, 8 9 public warehouseman or employee of the carrier or warehouseman.

10 (c-1) "Anabolic Steroids" means any drug or hormonal 11 substance, chemically and pharmacologically related to 12 testosterone (other than estrogens, progestins, and 13 corticosteroids) that promotes muscle growth, and includes:

14 (i) boldenone,

15 (ii) chlorotestosterone,

16 (iii) chostebol,

17 (iv) dehydrochlormethyltestosterone,

18 (v) dihydrotestosterone,

(vi) drostanolone, 19

20 (vii) ethylestrenol,

21 (viii) fluoxymesterone,

22 (ix) formebulone,

23 (x) mesterolone,

24 (xi) methandienone,

25 (xii) methandranone,

26 (xiii) methandriol,

1 (xiv) methandrostenolone, 2 (xv) methenolone, 3 (xvii) methyltestosterone, 4 (xvii) mibolerone, 5 (xviii) nandrolone, 6 (xix) norethandrolone, 7 (xx) oxandrolone, 8 (xxi) oxymesterone, 9 (xxii) oxymetholone, 10 (xxiii) stanolone, 11 (xxiv) testolactone, 12 (xxv) testolactone, 13 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 22 expressly intended for and lawfully allowed to be administered	1	
 (xvi) methyltestosterone, (xvii) mibolerone, (xviii) nandrolone, (xix) norethandrolone, (xix) oxandrolone, (xxi) oxymesterone, (xxi) oxymetholone, (xxii) oxymetholone, (xxiii) stanolone, (xxiv) stanozolol, (xxv) testolactone, (xxvi) testosterone, (xxvii) trenbolone, and (xxviii) any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, deliver an anabolic steroid, which anabolic steroid is 	1	(xiv) methandrostenolone,
 4 (xvii) mibolerone, 5 (xviii) nandrolone, 6 (xix) norethandrolone, 7 (xx) oxandrolone, 8 (xxi) oxymesterone, 9 (xxii) oxymetholone, 10 (xxiii) stanolone, 11 (xxiv) stanozolol, 12 (xxv) testolactone, 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 deliver an anabolic steroid, which anabolic steroid is 	2	(xv) methenolone,
5(xviii) nandrolone,6(xix) norethandrolone,7(xx) oxandrolone,8(xxi) oxymesterone,9(xxii) oxymetholone,10(xxiii) stanolone,11(xxiv) stanozolol,12(xxv) testolactone,13(xxvi) testosterone,14(xxvii) trenbolone, and15(xxviii) any salt, ester, or isomer of a drug or16substance described or listed in this paragraph, if17that salt, ester, or isomer promotes muscle growth.18Any person who is otherwise lawfully in possession of an19anabolic steroid, or who otherwise lawfully manufactures,20distributes, dispenses, delivers, or possesses with intent to21deliver an anabolic steroid, which anabolic steroid is	3	(xvi) methyltestosterone,
 (xix) norethandrolone, (xx) oxandrolone, (xxi) oxymesterone, (xxi) oxymetholone, (xxii) oxymetholone, (xxiii) stanolone, (xxiv) stanozolol, (xxv) testolactone, (xxv) testolactone, (xxvi) testosterone, (xxvii) trenbolone, and (xxviii) any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, distributes, dispenses, delivers, or possesses with intent to deliver an anabolic steroid, which anabolic steroid is 	4	(xvii) mibolerone,
 (xx) oxandrolone, (xxi) oxymesterone, (xxii) oxymetholone, (xxii) oxymetholone, (xxii) stanolone, (xxiv) stanozolol, (xxv) testolactone, (xxvi) testosterone, (xxvii) trenbolone, and (xxviii) any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, distributes, dispenses, delivers, or possesses with intent to deliver an anabolic steroid, which anabolic steroid is 	5	(xviii) nandrolone,
 8 (xxi) oxymesterone, 9 (xxii) oxymetholone, 10 (xxiii) stanolone, 11 (xxiv) stanozolol, 12 (xxv) testolactone, 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 	6	(xix) norethandrolone,
 9 (xxii) oxymetholone, 10 (xxiii) stanolone, 11 (xxiv) stanozolol, 12 (xxv) testolactone, 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 	7	(xx) oxandrolone,
 10 (xxiii) stanolone, 11 (xxiv) stanozolol, 12 (xxv) testolactone, 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 	8	(xxi) oxymesterone,
11 (xxiv) stanozolol, 12 (xxv) testolactone, 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is	9	(xxii) oxymetholone,
12 (xxv) testolactone, 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is	10	(xxiii) stanolone,
 13 (xxvi) testosterone, 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 	11	(xxiv) stanozolol,
 14 (xxvii) trenbolone, and 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 	12	(xxv) testolactone,
 15 (xxviii) any salt, ester, or isomer of a drug or 16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is 	13	(xxvi) testosterone,
16 substance described or listed in this paragraph, if 17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is	14	(xxvii) trenbolone, and
17 that salt, ester, or isomer promotes muscle growth. 18 Any person who is otherwise lawfully in possession of an 19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is	15	(xxviii) any salt, ester, or isomer of a drug or
Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, distributes, dispenses, delivers, or possesses with intent to deliver an anabolic steroid, which anabolic steroid is	16	substance described or listed in this paragraph, if
19 anabolic steroid, or who otherwise lawfully manufactures, 20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is	17	that salt, ester, or isomer promotes muscle growth.
20 distributes, dispenses, delivers, or possesses with intent to 21 deliver an anabolic steroid, which anabolic steroid is	18	Any person who is otherwise lawfully in possession of an
21 deliver an anabolic steroid, which anabolic steroid is	19	anabolic steroid, or who otherwise lawfully manufactures,
	20	distributes, dispenses, delivers, or possesses with intent to
22 expressly intended for and lawfully allowed to be administered	21	deliver an anabolic steroid, which anabolic steroid is
	22	expressly intended for and lawfully allowed to be administered

through implants to livestock or other nonhuman species, and which is approved by the Secretary of Health and Human Services for such administration, and which the person intends to administer or have administered through such implants, shall not be considered to be in unauthorized possession or to unlawfully manufacture, distribute, dispense, deliver, or possess with intent to deliver such anabolic steroid for purposes of this Act.

5 (d) "Administration" means the Drug Enforcement 6 Administration, United States Department of Justice, or its 7 successor agency.

8 (e) "Control" means to add a drug or other substance, or 9 immediate precursor, to a Schedule under Article II of this Act 10 whether by transfer from another Schedule or otherwise.

(f) "Controlled Substance" means a drug, substance, or immediate precursor in the Schedules of Article II of this Act.

(g) "Counterfeit substance" means a controlled substance, which, or the container or labeling of which, without authorization bears the trademark, trade name, or other identifying mark, imprint, number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the person who in fact manufactured, distributed, or dispensed the substance.

(h) "Deliver" or "delivery" means the actual, constructive
or attempted transfer of possession of a controlled substance,
with or without consideration, whether or not there is an
agency relationship.

(i) "Department" means the Illinois Department of Human
Services (as successor to the Department of Alcoholism and
Substance Abuse) or its successor agency.

(j) "Department of State Police" means the Department of
 State Police of the State of Illinois or its successor agency.

3

4

(k) "Department of Corrections" means the Department of Corrections of the State of Illinois or its successor agency.

5 (1) "Department of Professional Regulation" means the 6 Department of Professional Regulation of the State of Illinois 7 or its successor agency.

8

(m) "Depressant" or "stimulant substance" means:

9 (1) a drug which contains any quantity of (i) 10 barbituric acid or any of the salts of barbituric acid 11 which has been designated as habit forming under section 12 502 (d) of the Federal Food, Drug, and Cosmetic Act (21 13 U.S.C. 352 (d)); or

14 (2) a drug which contains any quantity of (i) 15 amphetamine or methamphetamine and any of their optical 16 isomers; (ii) any salt of amphetamine or methamphetamine or 17 any salt of an optical isomer of amphetamine; or (iii) any substance which the Department, after investigation, has 18 19 found to be, and by rule designated as, habit forming because of its depressant or stimulant effect on the 20 21 central nervous system; or

22

(3) lysergic acid diethylamide; or

(4) any drug which contains any quantity of a substance
which the Department, after investigation, has found to
have, and by rule designated as having, a potential for
abuse because of its depressant or stimulant effect on the

1

2

central nervous system or its hallucinogenic effect.

(n) (Blank).

3 (o) "Director" means the Director of the Department of 4 State Police or the Department of Professional Regulation or 5 his designated agents.

6 (p) "Dispense" means to deliver a controlled substance to 7 an ultimate user or research subject by or pursuant to the 8 lawful order of a prescriber, including the prescribing, 9 administering, packaging, labeling, or compounding necessary 10 to prepare the substance for that delivery.

11

(q) "Dispenser" means a practitioner who dispenses.

12 (r) "Distribute" means to deliver, other than by 13 administering or dispensing, a controlled substance.

14

(s) "Distributor" means a person who distributes.

(t) "Drug" means (1) substances recognized as drugs in the 15 16 official United States Pharmacopoeia, Official Homeopathic 17 Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; (2) substances 18 19 intended for use in diagnosis, cure, mitigation, treatment, or 20 prevention of disease in man or animals; (3) substances (other than food) intended to affect the structure of any function of 21 22 the body of man or animals and (4) substances intended for use 23 as a component of any article specified in clause (1), (2), or (3) of this subsection. It does not include devices or their 24 25 components, parts, or accessories.

26

(t-5) "Euthanasia agency" means an entity certified by the

Department of Professional Regulation for the purpose of animal 1 2 euthanasia that holds an animal control facility license or animal shelter license under the Animal Welfare Act. A 3 euthanasia agency is authorized to purchase, store, possess, 4 5 and utilize Schedule ΙI nonnarcotic and Schedule III 6 nonnarcotic drugs for the sole purpose of animal euthanasia.

7 (t-10) "Euthanasia drugs" means Schedule II or Schedule III
8 substances (nonnarcotic controlled substances) that are used
9 by a euthanasia agency for the purpose of animal euthanasia.

10 (u) "Good faith" means the prescribing or dispensing of a 11 controlled substance by a practitioner in the regular course of 12 professional treatment to or for any person who is under his 13 treatment for a pathology or condition other than that 14 individual's physical or psychological dependence upon or 15 addiction to a controlled substance, except as provided herein: 16 and application of the term to a pharmacist shall mean the 17 dispensing of a controlled substance pursuant to the prescriber's order which in the professional judgment of the 18 pharmacist is lawful. The pharmacist shall be guided by 19 20 accepted professional standards including, but not limited to 21 the following, in making the judgment:

22 (1) lack of consistency of doctor-patient 23 relationship,

(2) frequency of prescriptions for same drug by one
 prescriber for large numbers of patients,

26

(3) quantities beyond those normally prescribed,

1 (4) unusual dosages, 2 (5) unusual geographic distances between patient, 3 pharmacist and prescriber, (6) consistent prescribing of habit-forming drugs. 4 5 (u-1) "Home infusion services" means services provided by a pharmacy in compounding solutions for direct administration to 6 7 a patient in a private residence, long-term care facility, or 8 setting by means of parenteral, intravenous, hospice 9 intramuscular, subcutaneous, or intraspinal infusion. 10 (v) "Immediate precursor" means a substance: 11 (1) which the Department has found to be and by rule 12 designated as being a principal compound used, or produced 13 primarily for use, in the manufacture of a controlled 14 substance: 15 (2) which is an immediate chemical intermediary used or 16 likely to be used in the manufacture of such controlled 17 substance; and (3) the control of which is necessary to prevent, 18 limit the manufacture of such controlled 19 curtail or 20 substance. (w) "Instructional activities" means the acts of teaching, 21 22 educating or instructing by practitioners using controlled 23 substances within educational facilities approved by the State 24 Board of Education or its successor agency.

(x) "Local authorities" means a duly organized State,
County or Municipal peace unit or police force.

(y) "Look-alike substance" means a substance, other than a 1 2 controlled substance which (1) by overall dosage unit 3 appearance, including shape, color, size, markings or lack thereof, taste, consistency, or any other identifying physical 4 5 characteristic of the substance, would lead a reasonable person to believe that the substance is a controlled substance, or (2) 6 is expressly or impliedly represented to be a controlled 7 substance or is distributed under circumstances which would 8 9 lead a reasonable person to believe that the substance is a 10 controlled substance. For the purpose of determining whether 11 the representations made or the circumstances of the 12 distribution would lead a reasonable person to believe the 13 substance to be a controlled substance under this clause (2) of 14 subsection (y), the court or other authority may consider the 15 following factors in addition to any other factor that may be 16 relevant:

17

18

(a) statements made by the owner or person in controlof the substance concerning its nature, use or effect;

19 (b) statements made to the buyer or recipient that the20 substance may be resold for profit;

(c) whether the substance is packaged in a manner normally used for the illegal distribution of controlled substances;

(d) whether the distribution or attempted distribution
included an exchange of or demand for money or other
property as consideration, and whether the amount of the

1

2

consideration was substantially greater than the reasonable retail market value of the substance.

3 Clause (1) of this subsection (y) shall not apply to a 4 noncontrolled substance in its finished dosage form that was 5 initially introduced into commerce prior to the initial 6 introduction into commerce of a controlled substance in its 7 finished dosage form which it may substantially resemble.

8 Nothing in this subsection (y) prohibits the dispensing or 9 distributing of noncontrolled substances by persons authorized 10 to dispense and distribute controlled substances under this 11 Act, provided that such action would be deemed to be carried 12 out in good faith under subsection (u) if the substances 13 involved were controlled substances.

Nothing in this subsection (y) or in this Act prohibits the
manufacture, preparation, propagation, compounding,
processing, packaging, advertising or distribution of a drug or
drugs by any person registered pursuant to Section 510 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

19 (y-1) "Mail-order pharmacy" means a pharmacy that is 20 located in a state of the United States, other than Illinois, 21 that delivers, dispenses or distributes, through the United 22 States Postal Service or other common carrier, to Illinois 23 residents, any substance which requires a prescription.

(z) "Manufacture" means the production, preparation,
 propagation, compounding, conversion or processing of a
 controlled substance other than methamphetamine, either

directly or indirectly, by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling of its container, except that this term does not include:

7 8 (1) by an ultimate user, the preparation or compounding of a controlled substance for his own use; or

9 (2) by a practitioner, or his authorized agent under 10 his supervision, the preparation, compounding, packaging, 11 or labeling of a controlled substance:

12 (a) as an incident to his administering or
13 dispensing of a controlled substance in the course of
14 his professional practice; or

(b) as an incident to lawful research, teaching orchemical analysis and not for sale.

17 (z-1) (Blank).

18 (aa) "Narcotic drug" means any of the following, whether 19 produced directly or indirectly by extraction from substances 20 of natural origin, or independently by means of chemical 21 synthesis, or by a combination of extraction and chemical 22 synthesis:

(1) opium and opiate, and any salt, compound,
 derivative, or preparation of opium or opiate;

(2) any salt, compound, isomer, derivative, or
 preparation thereof which is chemically equivalent or

identical with any of the substances referred to in clause

(1), but not including the isoquinoline alkaloids of opium;

SB1355

2

1

3

(3) opium poppy and poppy straw;

(4) coca leaves and any salts, compound, isomer, salt 4 5 of an isomer, derivative, or preparation of coca leaves including cocaine or ecgonine, and any salt, compound, 6 isomer, derivative, or preparation thereof which is 7 8 chemically equivalent or identical with any of these 9 substances, but not including decocainized coca leaves or 10 extractions of coca leaves which do not contain cocaine or 11 ecgonine (for the purpose of this paragraph, the term 12 "isomer" includes optical, positional and geometric 13 isomers).

14 (bb) "Nurse" means a registered nurse licensed under the15 Nursing and Advanced Practice Nursing Act.

16 (cc) (Blank).

17 (dd) "Opiate" means any substance having an addiction 18 forming or addiction sustaining liability similar to morphine 19 or being capable of conversion into a drug having addiction 20 forming or addiction sustaining liability.

21 (ee) "Opium poppy" means the plant of the species Papaver 22 somniferum L., except its seeds.

23 (ff) "Parole and Pardon Board" means the Parole and Pardon24 Board of the State of Illinois or its successor agency.

25 (gg) "Person" means any individual, corporation, 26 mail-order pharmacy, government or governmental subdivision or agency, business trust, estate, trust, partnership or
 association, or any other entity.

3 (hh) "Pharmacist" means any person who holds a certificate 4 of registration as a registered pharmacist, a local registered 5 pharmacist or a registered assistant pharmacist under the 6 Pharmacy Practice Act of 1987.

7 (ii) "Pharmacy" means any store, ship or other place in
8 which pharmacy is authorized to be practiced under the Pharmacy
9 Practice Act of 1987.

10 (jj) "Poppy straw" means all parts, except the seeds, of 11 the opium poppy, after mowing.

12 (kk) "Practitioner" means a physician licensed to practice 13 branches, medicine in all its dentist, podiatrist, 14 veterinarian, medical psychologist, scientific investigator, 15 pharmacist, physician assistant, advanced practice nurse, 16 licensed practical nurse, registered nurse, hospital, 17 laboratory, or pharmacy, or other person licensed, registered, or otherwise lawfully permitted by the United States or this 18 19 State to distribute, dispense, conduct research with respect 20 to, administer or use in teaching or chemical analysis, a 21 controlled substance in the course of professional practice or 22 research.

(11) "Pre-printed prescription" means a written prescription upon which the designated drug has been indicated prior to the time of issuance.

26

(mm) "Prescriber" means a physician licensed to practice

medicine in all its branches, dentist, podiatrist, medical 1 2 psychologist, or veterinarian who issues a prescription, a 3 physician assistant who issues a prescription for a Schedule III, IV, or V controlled substance in accordance with Section 4 5 303.05 and the written guidelines required under Section 7.5 of the Physician Assistant Practice Act of 1987, or an advanced 6 7 practice nurse with prescriptive authority in accordance with Section 303.05 and a written collaborative agreement under 8 9 Sections 15-15 and 15-20 of the Nursing and Advanced Practice 10 Nursing Act.

11 (nn) "Prescription" means a lawful written, facsimile, or 12 verbal order of a physician licensed to practice medicine in all its branches, dentist, podiatrist, medical psychologist, 13 14 or veterinarian for any controlled substance, of a physician assistant for a Schedule III, IV, or V controlled substance in 15 16 accordance with Section 303.05 and the written guidelines 17 required under Section 7.5 of the Physician Assistant Practice Act of 1987, or of an advanced practice nurse who issues a 18 19 prescription for a Schedule III, IV, or V controlled substance 20 in accordance with Section 303.05 and a written collaborative agreement under Sections 15-15 and 15-20 of the Nursing and 21 22 Advanced Practice Nursing Act.

(oo) "Production" or "produce" means manufacture,
 planting, cultivating, growing, or harvesting of a controlled
 substance other than methamphetamine.

26

(pp) "Registrant" means every person who is required to

- 43 - LRB095 04986 RAS 25052 b

1 register under Section 302 of this Act.

2 (qq) "Registry number" means the number assigned to each
3 person authorized to handle controlled substances under the
4 laws of the United States and of this State.

5 (rr) "State" includes the State of Illinois and any state, 6 district, commonwealth, territory, insular possession thereof, 7 and any area subject to the legal authority of the United 8 States of America.

9 (ss) "Ultimate user" means a person who lawfully possesses 10 a controlled substance for his own use or for the use of a 11 member of his household or for administering to an animal owned 12 by him or by a member of his household.

13 (Source: P.A. 93-596, eff. 8-26-03; 93-626, eff. 12-23-03; 14 94-556, eff. 9-11-05.)